In spite of the gloomy economic, the Korean major pharmaceutical companies’ financial health has turned out generally good.
Especially, Bukwang Pharm's financial health was relatively excellent.
According to the Health Korea News' data analysis, the average debt ratio of 6 Korean pharmaceutical companies of last year (from April 2008 to March 2009) has recorded 72.44%, up 12.79% compared to the previous year(59.65%).
Among the 6 companies, Bukwang Pharm marked the lowest debt ratio of 33.16%, up 6.63% compared to the previous year(26.53%).
Dong Wha Pharm has also showed the relatively low debt ratio(51.68%).
Yuyu Pharma's debt ratio has decreased to 63.57%, down 11.43% compared to the previous year(75%).
Both Daewoong Pharm and Kukje Pharma has recorded less than 100% in their debt ratio(75.47% and 86.96% respectively).
And Il-Yang Pharm's debt ratio has recorded almost the same percent(123.79%) as the previous year(122.36%), even if it was the highest among the 6 companies.
In this data analysis, ILDONG Pharmaceutical is not included because its balance sheet will be posted after its general meeting of stockholders(26 June).<헬스코리아뉴스>